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RESEARCH
Cyathostomin resistance to moxidectin 
and combinations of anthelmintics in Australian 
horses
Ghazanfar Abbas1, Abdul Ghafar1, John Hurley2, Jenni Bauquier1, Anne Beasley3, Edwina J. A. Wilkes4, 
Caroline Jacobson5, Charles El‑Hage1, Lucy Cudmore6, Peter Carrigan6, Brett Tennent‑Brown1, Charles G. Gauci1, 
Martin K. Nielsen7, Kristopher J. Hughes4, Ian Beveridge1 and Abdul Jabbar1*  
Abstract 
Background: Cyathostomins are the most important and common parasitic nematodes of horses, with > 50 species 
known to occur worldwide. The frequent and indiscriminate use of anthelmintics has resulted in the development of 
anthelmintic resistance (AR) in horse nematodes. In this study we assessed the efficacy of commonly used anthelmin‑
tics against cyathostomins in Australian thoroughbred horses.
Methods: Two drug efficacy trials per farm were conducted on two thoroughbred horse farms in the state of Victoria, 
Australia. In the first trial, the horses on Farm A were treated with single and combinations of anthelmintics, including 
oxfendazole (OFZ), abamectin (ABM), abamectin and morantel (ABM + MOR), moxidectin (MOX) and oxfendazole and 
pyrantel (OFZ + PYR), at the recommended doses, whereas the horses on Farm B only received MOX, at the recom‑
mended dose. The faecal egg count reduction test (FECRT) was used to determine the efficacy and egg reappear‑
ance period (ERP) of anthelmintics. Based on the results of the first trial, the efficacies of MOX and a combination of 
ABM + MOR were reassessed to confirm their activities against cyathostomins.
Results: Of the five anthelmintic products tested on Farm A, resistance against OFZ, ABM and OFZ + PYR was found, 
with efficacies of − 41% (− 195% lower confidence limit [LCL]), 73% (60% LCL) and 82% (66% LCL) at 2 weeks post‑
treatment, respectively. The FECRT showed high efficacies of MOX and ABM + MOR (100%) at 2 week post‑treatment 
and shortened ERPs for these anthelmintics (ABM + MOR: 4 weeks; MOX: 5 weeks). Resistance to MOX was found on 
Farm B, with a reduced efficacy of 90% (70% LCL) and 89% (82% LCL) at 2 weeks post‑treatment in trials one and two, 
respectively.
Conclusions: This study provides the first evidence of MOX‑ and multidrug‑resistant (ABM and combinations of 
anthelmintics) cyathostomins in Australia and indicates the need for continuous surveillance of the efficacy of cur‑
rently effective anthelmintics and large‑scale investigations to assess the ERP for various anthelmintics.
Keywords: Australian thoroughbred horses, Cyathostomins, Egg reappearance period, Moxidectin, Resistance, FECRT 
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Background
Small strongyles (Strongylida: Cyathostominae), also 
known as cyathostomins, are the most important and 
common parasitic nematodes of horses, with more than 
50 species known to occur worldwide [1, 2]. Cyathos-
tomins have a direct life-cycle, with horses becoming 
infected by ingesting third-stage (L3) infective larvae 
while grazing and the infective larvae then developing 
into adult male and female worms in the large intestine. 
The majority of cyathostomin infections are subclinical, 
while clinical manifestations of larval cyathostominosis 
(i.e. synchronous emergence of fourth-stage larvae from 
the intestinal wall) include weight loss, colic, pyrexia, 
diarrhea and subcutaneous oedema accompanied by 
marked hypoproteinemia, with a case fatality of up to 
50% in horses of age ≤ 6 years [3, 4].
Control of cyathostomins in horses has traditionally 
relied on interval-based deworming using three classes 
of anthelmintics, benzimidazoles (BZs), tetrahydropy-
rimidines (THPs) and macrocyclic lactones (MLs) [5]. 
However, the frequent and indiscriminate use of anthel-
mintics has resulted in the development of anthelmin-
tic resistance (AR) in nematodes infecting horses [5]. 
Anthelmintic resistance against BZs and THPs is wide-
spread and well-established in cyathostomins, whereas 
sporadic accounts of resistance or reduced egg reappear-
ance periods (ERP) against MLs (ivermectin [IVM] and 
moxidectin [MOX]) have been reported from various 
parts of the world [6–8]. For example, ML resistance in 
cyathostomins has been reported either in a single horse 
[9] or in a group of horses at the farm level, based on 
drug efficacy trials [8, 10–15]. In addition, multiple stud-
ies have reported reduced ERP for cyathostomins after 
administration of IVM or MOX [11, 13–22].
Due to the growing concern of resistance against indi-
vidual anthelmintic drugs and/or classes, Barnes et  al. 
[23] and Leathwick [24] used computer simulation mod-
elling, with the results suggesting that combinations of 
≥ 2 anthelmintics with similar nematocidal spectrums 
from different classes could delay the development of 
resistance. This alternative approach was based on the 
successful control of resistant worms of sheep using 
combinations of anthelmintics before resistance lev-
els became too high [25, 26]. Although a combination 
of anthelmintics is now routinely used in some coun-
tries to control horse nematodes, limited information 
is available on the efficacy of such anthelmintic regi-
mens against cyathostomins. Kaplan et  al. [27] recently 
reported > 90%, > 95% and > 99% efficacies of the combi-
nation oxibendazole and pyrantel (OBZ + PYR) on 11, 9 
and 6 of 11 horse farms, respectively. Notably, the indi-
vidual efficacies of these drugs were < 90% [27]. Similarly, 
in another trial, an additive effect was observed for the 
efficacy of the OBZ + PYR combination against horse 
cyathostomins in the first of the four consecutive treat-
ments, whereas the individual efficacies of both drugs 
were much lower [28]. In addition, a recent simulation-
based study demonstrated that the use of a combination 
of anthelmintics could be helpful in delaying the develop-
ment of AR in cyathostomins, despite one of the active 
ingredients exhibiting lower efficacy [29].
Although there are numerous reports of AR and 
reduced ERP in cyathostomins of horses from various 
parts of the world, little is known about the status of 
resistance against MLs, particularly MOX, and combi-
nations of anthelmintics commonly used in Australian 
horses. Edward and Hoffmann [9] reported a suspected 
case of IVM resistance in cyathostomins based on post-
treatment faecal egg counts (FEC). Subsequently, Beasley 
et al. [22] reported reduced ERP for MOX (12 weeks) and 
IVM (6  weeks) against cyathostomins on one and two 
properties, respectively. These findings instigated a reg-
ular surveillance of the efficacy and ERP for commonly 
used anthelmintics in Australian horses. Therefore, the 
aim of this study was to assess the efficacy and ERP of 
commonly used anthelmintics on two thoroughbred 
horse farms in Australia.
Methods
Selection of horse farms
The following selection criteria were used to enroll the 
farms in the study: (i) horses had not been dewormed in 
the last 8–10 weeks; (ii) a confirmation that the FEC of 
an individual horse was ≥ 45 eggs per gram (EPG) of fae-
ces; and (iii) there was a known history of anthelmintic 
usage on the farm in the last 5 years (2015–2020). Horses 
selected for the study were assigned to treatment or 
control groups using simple randomisation. The control 
groups were selected to observe any natural variation in 
FECs of untreated horses during the study period.
This study was conducted during 2020–2021 on two 
thoroughbred horse farms (designated as A and B) in 
the state of Victoria, Australia where resident veterinar-
ians were interested in participating. Farm A is located 
200 km north of Melbourne and has approximately 600 
horses. Horses of all ages (adults, yearlings and wean-
lings) are dewormed based on average group FEC (i.e. 10 
faecal samples are randomly collected from each paddock 
and a FEC is performed on each sample). If the average 
EPG of faeces exceeds 500 EPG, all horses in the paddock 
are dewormed and the dose of anthelmintic is calculated 
according to herd-estimated average body weight in each 
age category. IVM and abamectin (ABM) and various 
anthelmintic combinations (oxfendazole and pyrantel 
[OFZ + PYR] and ABM and morantel [ABM + MOR]) 
have been used in the last 5 years (2015–2020), while a 
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combination of ABM and MOR has been used for all age 
groups of horses in the last year (2019). Continuous graz-
ing (i.e. set stocking) is used at the farm and horses are 
not moved out of the paddocks.
Farm B is located 110  km east of Melbourne and has 
approximately 60 thoroughbred horses. Adult horses 
on this farm are dewormed based on FEC surveil-
lance: horses with a FEC > 500 EPG are dewormed. On 
this farm, young horses are dewormed routinely every 
8–10  weeks, with the dose of anthelmintic for an indi-
vidual horse calculated based on actual body weight. In 
the last year (2019), MOX was used to deworm all age 
groups of horses. On Farm B, alternate grazing is used, 
and horses are periodically moved from one paddock to 
the other and replaced with cattle and alpacas.
Anthelmintic treatment and sample collection
Prior to the start of the study, FECs were performed at 
both farms to ascertain the worm egg count threshold 
required for the study. Anthelmintic dosage was calcu-
lated based on the individual horse body weight (Farm B) 
or weight of the heaviest animal within a treatment group 
(Farm A) and was administered as per the manufactur-
ers’ recommendations. The administration of anthelmin-
tics and the collection of faecal samples (directly from 
the rectum of the horses where possible) were performed 
by the resident farm veterinarians in the presence of the 
authors.
In the first trial conducted on Farm A, 30 weanlings (aged 
7–8 months; male = 12; female =  18) were selected and 
randomly divided into six groups (5 animals in each group) 
after fulfilling the inclusion criteria as outlined above. Five 
groups were treated with a single or a combination of 
anthelmintics, including OFZ, ABM, MOX, OFZ + PYR 
and ABM + MOR at recommended doses while the sixth 
group was an untreated control group (Table 1). For MOX, 
a formulation with a combination of praziquantel (PZQ) 
and MOX was used. Given PZQ has no nematocidal activ-
ity, we designated this combination as MOX throughout 
the paper. Faecal samples were collected on day 0 (immedi-
ately prior to treatment) and then weekly (apart from week 
4) until 6 weeks post-treatment (where no resistance was 
detected in the second or third weeks). On Farm B, 14 year-
lings (aged 12–13  months; male = 3; female =  11) were 
selected and randomly divided into two groups (7 animals 
in each group). One group was treated with MOX and the 
second group was an untreated control group.
Based on the findings of trial 1 on Farm A, the effica-
cies of MOX and ABM + MOR (Table 1) were re-tested in 
15 weanlings (aged 5–6 months; male = 7; female =  8) 8 
months after the first trial. For this purpose, the weanlings 
were divided into three groups (5 animals in each group), 
and two groups were treated with anthelmintics (MOX or 
ABM + MOR) while the third group was as an untreated 
control group. Similarly, a second trial was conducted on 
Farm B in which only the efficacy of MOX was re-tested 
in a group of 10 weanlings (aged 7–8  months; male = 3; 
female  =  7) 9 months after the first trial; the horses were 
divided into two groups (5 animals in each group), and one 
group was treated with MOX while the second group was 
an untreated control group.
Faecal egg counts
Faecal egg counts were carried out within 48 to 96 h of col-
lection of faeces using the Modified McMaster technique 
[30]. Briefly, 4 g of faeces was mixed with 4 ml of water to 
Table 1 Details of anthelmintic drugs used in this study
Group Trial(s) Drugs Active ingredient Dose (per kg body weight)
Farm A 1 AMMO Rotational Wormer® (Ceva Animal Health Pty 
Ltd, Glenorie, NSW, Australia)
Oxfendazole (OFZ) 10 mg
1 MecWorma & Bot® (International Animal Health Prod‑
ucts, Huntingwood, NSW, Australia)
Abamectin (ABM) 0.2 mg
1, 2 Strategy‑T® (Virbac Australia Pty Ltd, Peakhurst, NSW, 
Australia)
Oxfendazole and pyrantel (OFZ + PYR) 10 mg oxfenda‑
zole + 6.6 mg pyrantel 
base
1, 2 Equest® Plus Tape (Zoetis Australia Pty Ltd, Rhodes, 
NSW, Australia)
Moxidectin and praziquantel (MOX + PZQ) 0.4 mg
1 MecWorma & Tape® (International Animal Health 
Products)
Abamectin and morantel tartrate (ABM + MOR) 54 mg
2 AMMO Allwormer Wormer® (Ceva Animal Health Pty 
Ltd)
Abamectin and morantel tartrate (ABM + MOR) 54 mg
1, 2 Untreated control –
Farm B 1, 2 Equest® Plus Tape (Zoetis Australia, Pty Ltd) Moxidectin and praziquantel (MOX + PZQ) 0.4 mg
1, 2 Untreated control –
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make a homogeneous slurry which was then mixed with 
52  ml of sucrose solution (specific gravity = 1.27; www. 
csrsu gar. com. au) and homogenised using a spatula. Follow-
ing homogenisation, a sample (volume = 1 ml) was pipet-
ted into two chambers of a Whitlock egg counting slide 
(www. whitl ock. com. au). After 10 min, eggs were counted 
using a compound light microscope. A multiplication fac-
tor of 15 for this method was applied to calculate the num-
ber of eggs per gram.
FEC reduction test and ERP
The percentage FEC reduction (%FECR) was calculated 
each week to assess the efficacy of the anthelmintics tested, 
and resistance to a particular anthelmintic was declared as 
per the guidelines of the American Association of Equine 
Practitioners (AAEP) [31]. Briefly, group-based %FECR 
was calculated (utilising the equation below) using the 
arithmetic group mean FECs at pre-treatment and 2 weeks 
post-treatment to declare the efficacy of an anthelmintic in 
the group. The %FECR for each treatment group along with 
95% uncertainty interval was also analysed using the Bayes-
ian hierarchical model in an online web interface [32]:
Given that equine-specific criteria are yet to be estab-
lished to define the presence of resistance to individual 
MLs and drug combinations, an efficacy of %FECR 
of > 95% for MLs/drug combinations and > 90% for BZs/
THPs was used. Additionally, 95% lower confidence lim-
its (LCLs) of 90% and 80% were selected for classifying 
resistance to MLs/drug combinations and BZs/THPs, 
respectively, as per the guidelines of the World Asso-
ciation for the Advancement of Veterinary Parasitology 
(WAAVP) [33]. The 95% confidence intervals were cal-
culated based on the delta method as described by Lev-
ecke et  al. [34]. Resistance to a particular anthelmintic 
was confirmed if it failed to meet both thresholds, while 
a result where only one of the two criteria was met was 
considered to be suspected resistance. Likewise, there is 
no consensus on the calculation/interpretation of ERP in 
horses and no guidelines exist for setting a cut-off for the 
ERP of combination products. For this study, we adopted 
the standard where ERP is defined as the time elapsed 
from day 0 to when %FECR returns to < 90% [16].
Use of PCR for nematode identification
In order to rule out the presence of large strongyles 
(i.e. Strongylus spp.), a PCR targeting the second inter-
nal transcribed spacer (ITS-2) of the nuclear ribosomal 
DNA was performed as described previously [35]. DNA 
FECR% =
EPG(pre− treatment)− EPG(post − treatment)
EPG(pre− treatment)
× 100
was extracted from pre- and post-treatment pooled fae-
cal samples from each treated and untreated group using 
the DNeasy PowerSoil Pro Kit (Qiagen, Hilden, Ger-
many) according to the manufacturer’s protocol. PCRs 
were performed in a final volume of 25 µl using the 
Strongylus genus-specific primers NC4_F (5′-TGA AAT 
TKGAA CGA AT-3′) and NC2_R (5′- TTA GTT CTT TTC 
CTC CGC T-3′) in a T100 thermal cycler (BioRad Labo-
ratories, Hercules, CA, USA) using the same conditions 
as described by Campbell et  al. [35]. Known positive 
(genomic DNA of Strongylus edentatus) and negative 
(Milli-Q  H2O) controls were included in each PCR run. 
Aliquots (5  μl) of individual amplicons were analysed 
on 1.5% (w/v) agarose gels in Tris–Borate–EDTA buffer, 
stained with GelRed (Biotium, Fremont, CA, USA) and 
visualised using a GelDoc system (BioRad Laboratories).
Results
Anthelmintic efficacy
The weanlings on Farm A had pre-treatment FECs of 
cyathostomins ranging from 150 to 2730 EPG and from 
45 to 630 EPG for the first and second trials, respectively. 
In the first trial, resistance to OFZ (− 41% FECR; − 195% 
LCL), ABM (73% FECR; 60% LCL) and OFZ + PYR (82% 
FECR; 66% LCL) was observed 2 weeks post-treatment 
(Fig.  1). The %FECR based on Bayesian hierarchical 
model analysis using group mean FECs pre- and post-
treatment values resulted in the same efficacy as calcu-
lated by the method described in the AAEP parasite 
control guidelines. However, the former method also 
calculated the CI where efficacy was 100% (Table 2). The 
FEC of the majority of animals in each treatment group 
did not return to 0 EPG even by 1 week post-treatment. 
A consistent increase in individual horse EPG was noted 
in the following weeks for all anthelmintics tested, with 
the exception of MOX and ABM + MOR where cyathos-
tomin eggs reappeared in faeces at ≥ 3 weeks post-treat-
ment (Fig. 2).
On Farm B, the initial FEC of cyathostomins ranged 
from 75 to 3480 EPG and from 150 to 1455 EPG for year-
lings and weanlings, respectively. Resistance to MOX was 
found in both trials, with FECR of 90% (70% LCL) and 
89% (82% LCL) 2 weeks post-treatment in the first and 
second trials, respectively (Fig. 1).
The FECs of cyathostomins of horses included in the 
control group were found to be consistently positive 
throughout the study period in both trials, with no sign 
of a clinical disease.
Page 5 of 10Abbas et al. Parasites & Vectors          (2021) 14:597  
ERP for MOX and ABM + MOR
Out of five anthelmintic products tested in trial one on 
Farm A, only MOX and ABM + MOR resulted in 100% 
FECR 2 weeks post-treatment; therefore, we determined the 
ERP for these two anthelmintic products only. Three weeks 
post-treatment, one of the horses in the MOX-treated 
group tested positive for cyathostomin eggs; however, the 
group %FECR remained high at 99% and 100% for MOX 
and ABM + MOR, respectively. Subsequently, the sampling 
frequency was reduced to once every 2 weeks during trial 1 
Fig. 1 Efficacy of anthelmintics against cyathostomins on Farms A and B, based on 2‑weekly post‑treatment faecal egg counts. ABM, OFZ and 
OFZ + PYR were tested on Farm A while MOX was tested on Farm B. Each circle shows the percentage of the faecal egg count reduction (%FECR) 
for each anthelmintic at 2 weeks post‑treatment while each horizontal black line shows the upper and lower 95% confidence intervals. Lower 
confidence limits of < 0 were considered to be 0. The asterisk indicates the anthelmintic used in the second trial. ABM Abamectin, MOX moxidectin, 
OFZ oxfendazole, OFZ + PYR oxfendazole and pyrantel combination
Table 2 Cyathostomin faecal egg counts and percentage faecal egg count reduction at 2 weeks post‑treatment with 95% confidence 
intervals
AAEP American Association of Equine Practitioners, CI confidence interval, EGP eggs per gram, FEC faecal egg count, FECR faecal egg count reduction, N* number of 
horses in group, N** number of horses shedding eggs within a group 2 weeks post-treatment 





N** %FECR (95% CI) by AAEP 
method
%FECR (95% CI) Bayesian
hierarchical model
Mean Range Mean Range
Oxfendazole A 1 5 795 165–2730 1122 330–1890 5 − 41 (− 195 to − 57) 0 (0–5)
Abamectin A 1 5 774 315–1980 207 0–570 4 73 (60–84) 73 (65–79)
Moxidectin A 1 5 546 240–930 0 – 0 100 100 (98–100)
Abamectin + morantel A 1 5 561 150–1290 0 – 0 100 100 (98–100)
Oxfendazole + pyrantel A 1 5 870 150–2235 159 15–225 5 82 (66–92) 82 (76–86)
Moxidectin B 1 7 1530 75–3480 148 0–675 5 90 (70–99) 90 (88–93)
Moxidectin A 2 5 480 150–630 0 – 0 100 100 (98–100)
Abamectin + morantel A 2 5 162 45–450 0 – 0 100 100 (94–100)
Moxidectin B 2 5 1041 150–1455 117 75–165 5 89 (82–94) 89 (85–92)
Page 6 of 10Abbas et al. Parasites & Vectors          (2021) 14:597 
due to the labour required for the collection of faecal sam-
ples. At 5 weeks post-treatment, a sharp decrease in the effi-
cacies of both MOX and ABM + MOR was observed which 
continued into the sixth week (Fig. 3). Hence, the ERP for 
both MOX and ABM + MOR was considered to be 5 weeks 
in the first trial. In the second trial, post-treatment weekly 
%FECR data revealed that the ERP for ABM + MOR and 
MOX was 4 and 5 weeks, respectively (Fig. 3).
Identification of parasites
PCR amplicons revealed no band on 1.5% agarose gels in 
any of the pre- and post-treatment pooled faecal samples 
for all groups of horses while the positive control verified 
an expected amplicon size of approximately 370 bp, con-
firming that infections did not involve large strongyles.
Discussion
This is the first report of resistance in cyathostomins to 
ABM. This study not only provides evidence of resistance 
in cyathostomins to single anthelmintics (ABM, OFZ 
and MOX) but is the first account of multidrug resist-
ance in cyathostomins to treatment with a combina-
tion of anthelmintics (OFZ + PYR) on a single farm. The 
observed efficacies of OFZ, ABM, MOX and OFZ + PYR 
at 2 weeks post-treatment (− 41%, 73%, 90 and 89% and 
82%, respectively), were substantially lower than those 
used for declaring AR as outlined in the AAEP guidelines 
[31]. However, the efficacies of MOX and ABM + MOR 
were 100% at 2 weeks post-treatment in one trial, but 
those of both drugs decreased below the ERP cut-off lim-
its within 4–5 weeks post-treatment.
This study presents the first report of AR and mark-
edly reduced ERP for MLs (5 weeks for MOX) and a 
drug combination (4 weeks for ABM + MOR) in cyathos-
tomins in Australian horses while the manufacturer 
claimed ERP of at least 14  weeks for MOX in Australia 
[36]. Previously, only one study has reported reduced 
ERP of 6 and 12 weeks for IVM and MOX, respectively, 
in cyathostomins [22]. Since the introduction of MOX 
formulations for use in horses, reduced efficacy in treat-
ing cyathostomins in donkeys was first reported in an 
Fig. 2 Weekly faecal egg counts (eggs per gram of faeces) of cyathostomins in individual horses at day 0 up to 6 weeks post‑deworming for each 
anthelmintic used in both trials 1 and 2 at Farm A. Each circle represents the value of an individual faecal egg count per week
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abstract published in a conference proceedings [37], in 
which the mean %FECR in one of the treatment groups 
was 87% and 31% on 14 and 25  days post-treatment, 
respectively. However, this lower efficacy could be due 
to the off-label use of MOX (formulation for intramus-
cular use in cattle) which might have affected the phar-
macokinetics of the drug [38]. A recent study in Brazilian 
military horses reported resistance in cyathostomins to 
MOX; however, in this study anthelmintics were admin-
istered every 30 to 90  days and the study was started 
30  days following the last treatment, with the results 
possibly representing a selection bias for MOX-resistant 
cyathostomins [39]. In comparison, in our study, MOX 
registered for use in horses was used at the recommended 
dose rate, and selected horses had not been dewormed in 
the 8–10 weeks prior to the start of both trials. However, 
resistance to ABM and MOX was confirmed in wean-
lings and yearlings at the same farms. These resistant 
worms could have evolved as a result of intrinsic farm 
factors, such as selection pressure, frequent mutation 
events resulting in the recurrent appearance of pre-exist-
ing alleles in cyathostomins [40] or importation of such 
genotypes through the introduction of new horses onto 
the farms. Farm A is a large thoroughbred breeding farm 
where > 200 mares arrive for breeding each year from 
various local and interstate localities. Farm B routinely 
imports horses from other countries. Such horizontal 
transfer of resistant worms was recently demonstrated 
in a study assessing ML efficacy in cyathostomins on a 
US horse farm where resistance to IVM and MOX was 
detected in cyathostomins in yearlings recently imported 
from Ireland, suggesting the importation of resistant 
cyathostomins from Ireland to the USA [8].
Among various predisposing factors for the develop-
ment of AR in cyathostomins in this study, the frequency 
of deworming is likely a reason for the resistance to MOX 
as this anthelmintic was routinely used on Farm B for 
at least 1 year, with an interval of 8–10  weeks between 
treatments. In previous studies, the frequent use of 
anthelmintics was found to be associated with the devel-
opment of AR [41, 42]. Another plausible factor for the 
development of resistance in cyathostomins to MOX (as 
compared to other MLs) is the high efficacy of this drug 
against larvae [43–45], minimising refugia and lead-
ing to greater selection pressure for resistant worms. A 
recent simulation-based study found that climate, sea-
son and the number of treatments per year were key fac-
tors favouring the development of AR in cyathostomins 
[42]. Given Australia’s diverse climatic zones with pro-
found seasonal variations and the recommended interval 
for the deworming of horses being common across all 
of these zones, larger scale studies are needed to assess 
Fig. 3 The efficacy (%FECR) of MOX and the ABM + MOR combination at Farm A up to 5 and 6 weeks post‑treatment in trials 2 and 1, respectively. 
The 90% FECR threshold for defining the egg reappearance period is indicated with a black dotted line. The asterisk indicates the anthelmintic used 
in the second trial. ABM + MOR Abamectin and morantel combination
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the prevalence of AR in MLs, such as ABM and MOX, 
which are considered the last hope of ‘perceived’ effective 
anthelmintics against cyathostomins in horses.
The resistance to OFZ in cyathostomins found in this 
study is consistent with the results of previous studies 
which report widespread and well-established resistance 
patterns in cyathostomins against BZs [6, 46–49]. The 
resistance to OFZ might have contributed to the reduced 
efficacy of the OFZ + PYR combination (82% FECR) at 
2 weeks post-treatment in the current study. Although 
resistance was found to both OFZ and OFZ + PYR, the 
combination of anthelmintics yielded increased efficacy 
compared to OFZ alone. This additive efficacy could be 
due to preserved efficacy of PYR which was not tested 
alone due to its unavailability in Australia. A similar phe-
nomenon was observed previously by Scare et  al. [28] 
who reported enhanced efficacy (but still below effec-
tive limits: 76.6% FECR) of the OBZ + PYR combination 
against cyathostomins whereas the individual anthelmin-
tic efficacies were 66.7% and 63.3%, respectively. How-
ever, the maximum efficacy achieved was not sustained 
in successive trials, suggesting that combination therapy 
against a double resistant cyathostomin population is not 
sustainable.
For a timely diagnosis of AR, assessment of ERP is 
considered to be an early indicator [5]. In this study, we 
found reduced ERP for MOX and ABM + MOR on Farm 
A. Shortened ERP for cyathostomins following ML treat-
ments is widely reported in the literature. For example, 
an ERP of 4 weeks for cyathostomins following treatment 
with MOX has been reported in the USA [50]. Likewise, 
a European study reported an ERP of 6–8  weeks after 
treatment with MOX [51]. The longer ERP for MOX, in 
comparison to other ML drugs, is likely due to greater 
efficacy against various developmental stages of cyathos-
tomins. However, in a recent study, the efficacy of MOX 
against the immature stages of cyathostomins (late L3/
L4) was reduced, resulting in a decreased ERP [50], with 
the development of cross-resistance among MLs possibly 
contributing to the reduction in efficacy. The phenom-
enon of cross-resistance has been shown in Haemon-
chus contortus (a stomach nematode of sheep and goats), 
when rodents were infected with IVM-resistant and 
-susceptible strains of the parasite and then treated with 
MOX [52]. The authors found that MOX achieved an effi-
cacy of ≤ 47.2% against an IVM-resistant strain at a dose 
that invariably killed ≥ 98% of an IVM-susceptible strain, 
suggesting that worms resistant to one ML may likely be 
resistant to another ML [52]. More recently, resistance 
to MOX was found in cyathostomins following confir-
mation of IVM resistance in a group of imported horses 
[8]. The resistance to ABM alone found in the current 
study could have not only affected the efficacy of a related 
anthelmintic, i.e. MOX, but possibly also led to reduced 
efficacy of ABM + MOR on Farm A.
Although the efficacies of some anthelmintic products 
were re-assessed to ascertain the presence or absence 
of resistance, the findings of this study should be inter-
preted keeping in view possible limitations, such as (i) 
a small number of horses per treatment group and (ii) a 
low FEC threshold for the selection of animals. Further-
more, owing to the unavailability of single formulations 
of MOR and PYR for equines in Australia, we only tested 
available combinations of these drugs. Therefore, future 
studies should test the efficacy of single anthelmintics 
along with combinations, where available, using larger 
numbers of animals per treatment group and a higher 
FEC threshold.
Conclusion
This study provides the first report of resistance to ABM, 
MOX and a combination of anthelmintics in cyathos-
tomins. MOX is arguably the last effective anthelmintic 
to manage cyathostomins in horses; however resistance 
was detected on more than one occasion in this study. The 
detection of cyathostomin resistance and/or reduced ERP 
to MLs (when used as a single anthelmintic and in combi-
nation) are concerning, and warrant the use of alternative 
worm control strategies. Further field studies involving a 
greater number of horses per group are required to assess 
the prevalence of resistance to single and multiple anthel-
mintics in cyathostomin populations. Consensus on FEC-
based methods and interpretation of the detection of 
reduced drug efficacy/resistance, i.e. FECRT and ERP, are 
required to facilitate the monitoring, reporting and com-
parison of data between studies.
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